{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:39:11Z","timestamp":1793817551922,"version":"4.6.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"4","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, has shown clinical benefit in patients with relapsed or refractory (R\/R) B-cell lymphomas. The phase 2 CITADEL-204 study (NCT03144674, EudraCT 2017-000970-12) assessed efficacy and safety of parsaclisib in Bruton tyrosine kinase (BTK) inhibitor\u2013experienced (cohort 1) or BTK inhibitor\u2013naive (cohort 2) patients with R\/R marginal zone lymphoma (MZL). Patients aged \u226518 years with histologically confirmed R\/R MZL, treated with \u22651 prior systemic therapy (including \u22651 anti-CD20 antibody) received parsaclisib 20\u00a0mg once daily for 8\u00a0weeks then 20\u00a0mg once weekly (weekly dosing group [WG]) or parsaclisib 20\u00a0mg once daily for 8\u00a0weeks then 2.5\u00a0mg once daily (daily dosing group [DG]); DG was selected for further assessment. Primary end point of the study was objective response rate (ORR). Owing to slower than expected recruitment, cohort 1 was closed with 10 patients (WG, n\u00a0= 4; DG, n\u00a0= 6) enrolled. Based on a planned interim analysis in cohort 2, the futility boundary was not crossed, and enrollment continued to study completion. At data cutoff (15 January 2021), 100 patients were enrolled and treated in cohort 2 (WG, n\u00a0= 28; DG, n\u00a0= 72). In the DG, the ORR was 58.3% (95% confidence interval [CI], 46.1-69.8), with a complete response rate of 4.2% (95%\u00a0CI, 0.9-11.7); the lower bound of the ORR 95%\u00a0CI exceeded the protocol-defined threshold of 40%. The median duration of response was 12.2\u00a0months (95%\u00a0CI, 8.1-17.5) and progression-free survival was 16.5\u00a0months (95%\u00a0CI, 11.5-20.6); median overall survival was not reached. The most common treatment-emergent adverse events (TEAEs) among all patients were diarrhea (47.0%), cough (23.0%), and rash (18.0%); the most common grade \u22653 TEAEs included diarrhea (12.0%), neutropenia, and pneumonia (9.0% each). TEAEs led to dose interruptions, reductions, and discontinuations in 56.0%, 16.0%, and 29.0% of all patients, respectively. Durable responses and an overall manageable safety profile were demonstrated in patients with R\/R MZL treated with parsaclisib monotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010648","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T21:17:25Z","timestamp":1703020645000},"page":"867-877","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["A phase 2 study of the PI3K\u03b4 inhibitor parsaclisib in\u00a0relapsed and refractory marginal zone lymphoma (CITADEL-204)"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-9672","authenticated-orcid":false,"given":"Tycel J.","family":"Phillips","sequence":"first","affiliation":[{"name":"1Rogel Cancer Center, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Avigdor","sequence":"additional","affiliation":[{"name":"2Institute of Hematology, Sheba Medical Center, Ramat Gan, Israel"},{"name":"3Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Gurion","sequence":"additional","affiliation":[{"name":"4Institute of Hematology, Rabin Medical Center & Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[{"name":"5Department of Hematology I, Azienda Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"6University of Milano Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[{"name":"7Ospedale di Ravenna, Azienda Unit\u00e0 Sanitaria Locale della Romagna, Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0537-4207","authenticated-orcid":false,"given":"Amitkumar","family":"Mehta","sequence":"additional","affiliation":[{"name":"8University of Alabama School of Medicine, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"9Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"10IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Bologna, Italy"},{"name":"11Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"12Universit\u00e9 de Paris; APHP, H\u00f4pital Saint-Louis, H\u00e9mato-oncologie, Paris Diderot, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"13Maria Sklodowska-Curie National Research Institute of Oncology, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Zheng","sequence":"additional","affiliation":[{"name":"14Incyte Corporation, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Rappold","sequence":"additional","affiliation":[{"name":"14Incyte Corporation, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Zhao","sequence":"additional","affiliation":[{"name":"14Incyte Corporation, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Jiang","sequence":"additional","affiliation":[{"name":"14Incyte Corporation, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2306-4974","authenticated-orcid":false,"given":"Peter","family":"Johnson","sequence":"additional","affiliation":[{"name":"15School of Cancer Sciences, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"issue":"suppl 1","key":"2024022615161355500_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-134451","article-title":"Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory marginal zone lymphoma (CITADEL-204)","volume":"136","author":"Phillips","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2024022615161355500_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2021-147778","article-title":"Efficacy and safety of parsaclisib in patients with relapsed or refractory marginal zone lymphoma: primary analysis from a phase 2 study (CITADEL-204)","volume":"138","author":"Phillips","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024022615161355500_bib3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1586\/14737140.2015.1023712","article-title":"New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy","volume":"15","author":"Chihara","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"2024022615161355500_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"key":"2024022615161355500_bib5","unstructured":"National Comprehensive Cancer Network Guidelines\n          . Referenced With Permission From the NCCN Clinical Practice Guidelines in Oncology B-Cell Lymphomas Version 4. Accessed 12 April 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"issue":"16","key":"2024022615161355500_bib6","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"2024022615161355500_bib7","unstructured":"REVLIMID (lenalidomide) capsules for oral use. Prescribing information. Celgene Corporation. 2022. Accessed 24 November 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/021880s065lbl.pdf."},{"issue":"14","key":"2024022615161355500_bib8","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"2024022615161355500_bib9","unstructured":"BRUKINSA (zanubrutinib) capsules, for oral use. Prescribing information. BeiGene USA, Inc. 2022. Accessed 24 November 2022. https:\/\/www.brukinsa.com\/prescribing-information.pdf."},{"issue":"23","key":"2024022615161355500_bib10","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2024022615161355500_bib11","unstructured":"Update on IMBRUVICA (ibrutinib) U.S. accelerated approvals for mantle cell lymphoma and marginal zone lymphoma indications. Janssen Pharmaceutical Companies of Johnson & Johnson. 6 April 2023. Accessed 19 June 2023. https:\/\/www.jnj.com\/update-on-imbruvica-ibrutinib-u-s-accelerated-approvals-for-mantle-cell-lymphoma-and-marginal-zone-lymphoma-indications."},{"issue":"5","key":"2024022615161355500_bib12","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2024022615161355500_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2020.08.022","article-title":"Can next-generation PI3K inhibitors unlock the full potential of the class in patients with B-cell lymphoma?","volume":"21","author":"Phillips","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2024022615161355500_bib14","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024022615161355500_bib15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ajh.25711","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","volume":"95","author":"Dreyling","year":"2020","journal-title":"Am J Hematol"},{"issue":"15","key":"2024022615161355500_bib16","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024022615161355500_bib17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/bloodadvances.2020002910","article-title":"Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma","volume":"5","author":"Panayiotidis","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"2024022615161355500_bib18","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1021\/acsmedchemlett.9b00334","article-title":"INCB050465 (parsaclisib), a novel next-generation inhibitor of phosphoinositide 3-kinase delta (PI3K\u03b4)","volume":"10","author":"Yue","year":"2019","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"2024022615161355500_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1124\/jpet.120.265538","article-title":"Parsaclisib is a next-generation phosphoinositide 3-kinase \u03b4 inhibitor with reduced hepatotoxicity and potent antitumor and immunomodulatory activities in models of B-cell malignancy","volume":"374","author":"Shin","year":"2020","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"16","key":"2024022615161355500_bib20","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"133","author":"Forero-Torres","year":"2019","journal-title":"Blood"},{"issue":"27","key":"2024022615161355500_bib21","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"2024022615161355500_bib22","doi-asserted-by":"crossref","first-page":"102130","DOI":"10.1016\/j.eclinm.2023.102130","article-title":"Parsaclisib, a PI3K\u03b4 inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study","volume":"63","author":"Trn\u011bn\u00fd","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"11","key":"2024022615161355500_bib23","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024022615161355500_bib24","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1470-2045(22)00333-3","article-title":"Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial","volume":"23","author":"Pagel","year":"2022","journal-title":"Lancet Oncol"},{"key":"2024022615161355500_bib25","first-page":"62:102131","article-title":"Parsaclisib, a PI3K\u03b4 inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study","author":"Zinzani","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"15","key":"2024022615161355500_bib26","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024022615161355500_bib27","article-title":"Secura Bio announces Copiktra (duvelisib) strategic focus on T-cell lymphoma and voluntary U.S. withdrawal of the relapsed or refractory follicular lymphoma indication","year":"3  2021.  24  2022","journal-title":"Secura Bio, Inc"},{"key":"2024022615161355500_bib28","article-title":"Gilead statement on Zydelig U.S. indication for follicular lymphoma and small lymphocytic leukemia","year":"14  2022.  24  2022","journal-title":"Gilead Sciences Inc"},{"key":"2024022615161355500_bib29","article-title":"TG Therapeutics announces voluntary withdrawal of the BLA\/sNDA for U2 to treat patients with CLL and SLL","year":"15  2022.  24  2022","journal-title":"TG Therapeutics Inc"},{"key":"2024022615161355500_bib30","unstructured":"US Food and Drug Administration\n          . Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Hematologic Malignancies. ODAC briefing document. Accessed 16 June 2022. https:\/\/www.fda.gov\/media\/157762\/download."},{"issue":"5","key":"2024022615161355500_bib31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(22)00200-5","article-title":"The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024022615161355500_bib32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.18368","article-title":"A\u00a0phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","volume":"199","author":"Strati","year":"2022","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/4\/867\/2215175\/blooda_adv-2023-010648-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/4\/867\/2215175\/blooda_adv-2023-010648-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T15:16:31Z","timestamp":1708960591000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/4\/867\/506667\/A-phase-2-study-of-the-PI3K-inhibitor-parsaclisib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,2,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010648","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}